Book a Meeting

Non-Fucosylated Anti-Human Syndecan 1 (587CT11.3.6) Therapeutic Antibody (CAT#: BioBet-1264ZP) Datasheet

Target
Syndecan 1
Isotype
IgG
Description
ADCC-Enhanced anti-Syndecan 1 (587CT11.3.6) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Cancer
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Syndecan 1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
SDC1
Full Name
syndecan 1
Background
The protein encoded by this gene is a transmembrane (type I) heparan sulfate proteoglycan and is a member of the syndecan proteoglycan family. The syndecans mediate cell binding, cell signaling, and cytoskeletal organization and syndecan receptors are required for internalization of the HIV-1 tat protein. The syndecan-1 protein functions as an integral membrane protein and participates in cell proliferation, cell migration and cell-matrix interactions via its receptor for extracellular matrix proteins. Altered syndecan-1 expression has been detected in several different tumor types. While several transcript variants may exist for this gene, the full-length natures of only two have been described to date. These two represent the major variants of this gene and encode the same protein.
Alternative Names
SDC1; syndecan 1; SDC; CD138; SYND1; syndecan; syndecan-1; CD138 antigen; syndecan proteoglycan 1; heparan sulfate proteoglycan fibroblast growth factor receptor
Gene ID
6382
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with SDC1 include Monoclonal Gammopathy Of Uncertain Significance and Granulomatous Endometritis.
Related Pathways
Its related pathways are Signaling by GPCR and Development HGF signaling pathway.
Function
Cell surface proteoglycan that bears both heparan sulfate and chondroitin sulfate and that links the cytoskeleton to the interstitial matrix. Regulates exosome biogenesis in concert with SDCBP and PDCD6IP
Field of research
Cancer antibody; Developmental Biology antibody; Metabolism antibody; Neuroscience antibody; Signaling Transduction antibody
Post-translational modifications
Shedding is enhanced by a number of factors such as heparanase, thrombin or EGF. Also by stress and wound healing. PMA-mediated shedding is inhibited by TIMP3.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
587CT11.3.6
Host
Humanized
Species Reactivity
Human
Description
The anti-CD138 monoclonal can be used in prediction, diagnosis, treatment and prognosis of cancer.
Indication
Cancer

Cancer

Related Products

Non-Fucosylated Anti-Human Syndecan 1 (480CT5.4.3) Therapeutic Antibody (CAT#: BioBet-1265ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany